Enzon News
06/22/2009
Enzon Commences Phase II Trial of PEG-SN38
-- Conference Call With Principal Investigators to be Held Tomorrow-- MORE
Enzon Commences Phase II Trial of PEG-SN38
-- Conference Call With Principal Investigators to be Held Tomorrow-- MORE
06/01/2009
Enzon Presents Clinical Data from HIF-1 Alpha Antagonist Study at ASCO
-- First specific HIF-1a inhibitor is well tolerated with early signs of clinical benefit-- MORE
Enzon Presents Clinical Data from HIF-1 Alpha Antagonist Study at ASCO
-- First specific HIF-1a inhibitor is well tolerated with early signs of clinical benefit-- MORE
Stock Information
| (ENZN) NASDAQ | |||
| Last Trade | 7.84 | ||
| Change(%) |  | -0.20 | |
| Volume | 187206 | ||
| 6:40 PM - Jul 03, 2009 | |||
Investor Relations
The 2008 Enzon annual report is available to read online.
MORE
MORE
Mailing List
Enter your email address to sign up for the Enzon mailing list.